

DNA sequence which hybridize with it and/or show a significant homology with this sequence or fragments of it and which code for a protein with the same function.

Claim 7 (amended) DNA sequence according to claim 1 comprising modifications introduced by suppression, insertion and/or substitution of at least one nucleotide coding for a protein with the same biological activity as human transcription factor hTFIIIA.

Claim 8 (amended) DNA sequence according to claim 1 as well as similar DNA sequences which have nucleotide sequence homology of at least 50% or at least 60% and preferably at least 70% with the said DNA sequence.

Claim 9 (amended) DNA sequence according to claim 1 as well as similar DNA sequences which code for a protein, the AA sequence of which has a homology of at least 40% and in particular 45% or at least 50%, rather at least 60% and preferably at least 70% with the AA sequence coded by the said DNA sequence.

Claim 10 (amended) Polypeptide having the function of human transcription factor hTFIIIA and with the amino acid sequence SEQ ID No: 2 coded by the DNA sequence according to claim 1 and the analogues of this polypeptide.

Claim 11 (amended) Process for the preparation of the hTFIIIA recombinant protein having the amino acid sequence SEQ ID No: 2 comprising the expression of the DNA sequence according to claim 1 in an appropriate host, then isolation and purification of the said recombinant protein.

*A* 2  
Claim 12 (amended) Expression vector containing the DNA sequence according to claim 3.

Cancel claims 15 and 16 and add the following claims:

*Q3* --17. A method of treating a disease linked to transcription control disorders in warm-blooded animals comprising administering to warm-blooded animals in need thereof an amount of the (DNA sequence of claim 1 or the human transcription factor coded by the sequence sufficient to treat said diseases.) *RWW*

18. The method of claim 17 wherein the disease is cancer.--

REMARKS

The amendment is presented to insert reference to the PCT application, to remove multiple dependency from the claims and to present proper method of use claims. A marked up copy of the amended claims is submitted herewith.

Respectfully submitted,  
Bierman, Muserlian and Lucas

By: *Charles A. Muserlian*  
Charles A. Muserlian #19,683  
Attorney for Applicants  
Tel.# (212) 661-8000

CAM:ds  
Enclosures